Compare Bank of America Corp (BAC) vs Pfizer Inc (PFE) Price & Performance

Bank of America (BAC) trades at $63.17, up 0.27% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates solid fundamental performance with Q2 2026 EPS beating expectations at $1.21 versus $1.13, marking the third consecutive quarterly beat. Revenue growth accelerated to $113.1 billion in 2025, with net income reaching $30.51 billion. Recent developments include strategic partnerships with FIFA and continued investment in talent acquisition.

BAC presents a compelling investment case with analyst consensus strongly favoring buy ratings (64.82%) and a $67.36 price target offering 6.6% upside. The bank's massive deposit franchise and improving net interest margins support earnings growth. Key risks include sensitivity to interest rate changes and potential regulatory changes from upcoming stress tests. The stock's current valuation at 14.59 P/E appears reasonable given earnings momentum.

Pfizer (PFE) trades at $26.74, up 2.06% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. Recent quarters show consistent earnings beats, though revenue has moderated from pandemic peaks. The company maintains a strong cash position of $20.48 billion (2024) and a dividend yield supported by a $0.43 per share payout. Key developments include a focus on obesity and oncology pipelines, with several catalysts expected in 2026.

The outlook balances a stable dividend and pipeline potential against post-COVID revenue normalization and patent cliff risks. Near-term upside exists if pipeline catalysts materialize, but investors face headwinds from competitive pressures and projected net income margin compression to 6.8% in 2026. The stock's valuation at a P/E of 35.21 appears elevated relative to earnings growth, warranting caution despite technical strength.